Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Colorcon

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Elbasvir; grazoprevir - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for elbasvir; grazoprevir and what is the scope of patent protection?

Elbasvir; grazoprevir is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Elbasvir; grazoprevir has one hundred and three patent family members in forty-two countries.

One supplier is listed for this compound.

Summary for elbasvir; grazoprevir
International Patents:103
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 57
DailyMed Link:elbasvir; grazoprevir at DailyMed
Recent Clinical Trials for elbasvir; grazoprevir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sanjay Gandhi Postgraduate Institute of Medical SciencesPhase 3
Radboud UniversityPhase 1
Albert Einstein Healthcare NetworkPhase 4

See all elbasvir; grazoprevir clinical trials

US Patents and Regulatory Information for elbasvir; grazoprevir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Merck Sharp Dohme ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for elbasvir; grazoprevir

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2410844 2017006 Norway   Start Trial PRODUCT NAME: ELBASVIR ELLER ET FARMASOEYTISK; REG. NO/DATE: EU/1/16/1119 20160804
2310095 PA2016049,C2310095 Lithuania   Start Trial PRODUCT NAME: GRAZOPREVIRAS ARBA FARMACISKAI PRIIMTINOS JO DRUSKOS; NAT. REGISTRATION NO/DATE: CH/65861 01 20160401; FIRST REGISTRATION: EU/1/16/1119 20160722
2310095 C20160051 00215 Estonia   Start Trial PRODUCT NAME: GRASOPREVIIR;REG NO/DATE: EU/1/16/1119 26.07.2016
2310095 1690068-0 Sweden   Start Trial PRODUCT NAME: GRAZOPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Merck
Medtronic
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.